Compare AstraZeneca plc (AZN) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Endeavour Silver Corp — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while Endeavour Silver Corp trades at $8.01 (market cap $2.39B). The key difference: AstraZeneca plc is far larger — about 105.9× Endeavour Silver Corp's market cap, and AstraZeneca plc pays a 1.92% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| AZN | EXK | |
|---|---|---|
Market Cap | $253.13B | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $14.12 |
52-Week Low | $137.44 | $4.96 |
Enterprise Value | $279.37B | $2.40B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EXK trades at $7.84, down 2.97% on the day, amid a bearish technical signal. The company reported strong Q1 2026 results with earnings of $0.21 per share beating estimates, driven by record production. However, full-year 2025 financials show a net loss of $119.10 million. Analyst sentiment is largely positive with 11 buy ratings, but the stock faces headwinds from negative profitability metrics and high valuation multiples.
The outlook is mixed; operational improvements and silver price trends offer upside, but persistent losses and bearish technicals pose risks. Investors should weigh the company's growth potential against its current financial health and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
